DOCSLIB.ORG

WO 2013/151671 Al 10 October 2013 (10.10.2013) P O P C T

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
WO 2013/151671 Al 10 October 2013 (10.10.2013) P O P C T (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/151671 Al 10 October 2013 (10.10.2013) P O P C T (51) International Patent Classification: 61/681,704 10 August 2012 (10.08.2012) US A61K 31/7115 (2006.01) 61/681,720 10 August 2012 (10.08.2012) us 61/681,742 10 August 2012 (10.08.2012) us (21) International Application Number: 61/681,645 10 August 2012 (10.08.2012) us PCT/US20 13/030068 61/681,650 10 August 2012 (10.08.2012) us (22) International Filing Date: 61/681,661 10 August 2012 (10.08.2012) us March 2013 (09.03.2013) 61/681,648 10 August 2012 (10.08.2012) us 61/681,712 10 August 2012 (10.08.2012) us (25) Filing Language: English 61/696,381 4 September 2012 (04.09.2012) us (26) Publication Language: English 61/709,303 3 October 2012 (03. 10.2012) us 61/712,490 11 October 2012 ( 11.10.2012) us (30) Priority Data: 61/737,168 14 December 2012 (14. 12.2012) us 61/618,862 2 April 2012 (02.04.2012) US 61/737,203 14 December 2012 (14. 12.2012) us 61/618,866 2 April 2012 (02.04.2012) US 61/737,155 14 December 2012 (14. 12.2012) us 61/618,868 2 April 2012 (02.04.2012) us 61/737,213 14 December 2012 (14. 12.2012) us 61/618,870 2 April 2012 (02.04.2012) us 61/737,139 14 December 2012 (14. 12.2012) us 61/618,873 2 April 2012 (02.04.2012) us 61/737,174 14 December 2012 (14. 12.2012) us 61/618,878 2 April 2012 (02.04.2012) us 61/737,135 14 December 2012 (14. 12.2012) us 61/618,885 2 April 2012 (02.04.2012) us 61/737,152 14 December 2012 (14. 12.2012) us 61/618,896 2 April 2012 (02.04.2012) us 61/737,184 14 December 2012 (14. 12.2012) us 61/618,91 1 2 April 2012 (02.04.2012) us 61/737,160 14 December 2012 (14. 12.2012) us 61/618,922 2 April 2012 (02.04.2012) us 61/737,130 14 December 2012 (14. 12.2012) us 61/618,935 2 April 2012 (02.04.2012) us 61/737,191 14 December 2012 (14. 12.2012) us 61/618,945 2 April 2012 (02.04.2012) us 61/737,134 14 December 2012 (14. 12.2012) us 61/618,953 2 April 2012 (02.04.2012) us 61/737,147 14 December 2012 (14. 12.2012) us 61/618,961 2 April 2012 (02.04.2012) us 61/618,957 2 April 2012 (02.04.2012) us Applicant: MODERNA THERAPEUTICS [US/US]; 161 First Street, First Floor, Cambridge, MA 02142 (US). 61/648,286 17 May 2012 (17.05.2012) us 61/648,244 17 May 2012 (17.05.2012) us (72) Inventors: BANCEL, Stephane; 68 Pinckney Road, Bo 61/668,157 5 July 2012 (05.07.2012) us ston, MA 021 14 (US). HUANG, Eric, Yi-Chun; 90 Ware- 61/681,667 10 August 2012 (10.08.2012) us ham Street #302, Boston, MA 021 18 (US). 61/681,647 10 August 2012 (10.08.2012) us 61/681,675 10 August 2012 (10.08.2012) us (74) Agent: WARD, Donna, T.; DT WARD, P.C., 142A Main 61/681,654 10 August 2012 (10.08.2012) us Street, Groton, MA 01450 (US). 61/681,687 10 August 2012 (10.08.2012) us (81) Designated States (unless otherwise indicated, for every 10 August 2012 (10.08.2012) 61/681,649 us kind of national protection available): AE, AG, AL, AM, 61/681,696 10 August 2012 (10.08.2012) us AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, 61/681,658 10 August 2012 (10.08.2012) us [Continued on nextpage] (54) Title: MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF COSMETIC PROTEINS AND PEPTIDES 100 Figure 1 108 n o (57) Abstract: Described herein are compositions, methods, processes, kits and devices for the design, preparation, manufacture and/or formulation of modified mRNA (mmRNA) molecules encoding at least one cosmetic polypeptide of interest. The present in o vention provides a method of treating a disease, disorder and/or condition in a subject in need thereof by increasing the level of at least one cosmetic polypeptide of interest comprising administering to said subject an isolated polynucleotide selected from the group consisting of SEQ ID NOs 884-161 1 and 5691-5707 comprising, a first region of linked nucleosides, said first region encod o ing the cosmetic polypeptide of interest, a first flanking region located at the 5' terminus of said first region comprising a sequence of linked nucleosides selected from the group consisting of the native 5' untranslated region (UTR). w o 2013/151671 A I llI II III ill III III III III BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, GW, ML, MR, NE, SN, TD, TG). RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, Published: ZA, ZM, ZW. — with international search report (Art. 21(3)) (84) Designated States (unless otherwise indicated, for every — with sequence listing part of description (Rule 5.2(a)) kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF COSMETIC PROTEINS AND PEPTIDES REFERENCE TO SEQUENCE LISTING [0001] The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing file entitled MNCl_20SQLST.txt, created on March 09, 2013 which is 17,037,558 bytes in size. The information in electronic format of the sequence listing is incorporated herein by reference in its entirety. CROSS REFERENCE TO RELATED APPLICATIONS [0002] This application claims priority to U.S. Provisional Patent Application No 61/681,742, filed, August 10, 2012, entitled Modified Polynucleotides for the Production of Oncology-Related Proteins and Peptides, U.S. Provisional Patent Application No 61/737,224, filed December 14, 2012, entitled Terminally Optimized Modified RNAs, International Application No PCT/US2012/069610, filed December 14, 2012, entitled Modified Nucleoside, Nucleotide, and Nucleic Acid Compositions, U.S. Provisional Patent Application No 61/618,862, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Biologies, U.S. Provisional Patent Application No 61/681,645, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Biologies, U.S. Provisional Patent Application No 61/737,130, filed December 14, 2012, entitled Modified Polynucleotides for the Production of Biologies, U.S. Provisional Patent Application No 61/618,866, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Antibodies, U.S. Provisional Patent Application No 61/681,647, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Antibodies, U.S. Provisional Patent Application No 61/737,134, filed December 14, 2012, entitled Modified Polynucleotides for the Production of Antibodies, U.S. Provisional Patent Application No 61/618,868, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Vaccines, U.S. Provisional Patent Application No 61/681,648, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Vaccines, U.S. Provisional Patent Application No 61/737,135, filed December 14, 2012, entitled Modified Polynucleotides for the Production of Vaccines, U.S. Provisional Patent Application No 61/618,870, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Therapeutic Proteins and Peptides, U.S. Provisional Patent Application No 61/681,649, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Therapeutic Proteins and Peptides, U.S. Provisional Patent Application No 61/737,139, filed December 14, 2012, Modified Polynucleotides for the Production of Therapeutic Proteins and Peptides, U.S. Provisional Patent Application No 61/618,873, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Secreted Proteins, U.S. Provisional Patent Application No 61/681,650, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Secreted Proteins, U.S. Provisional Patent Application No 61/737,147, filed December 14, 2012, entitled Modified Polynucleotides for the Production of Secreted Proteins, U.S. Provisional Patent Application No 61/618,878, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Plasma Membrane Proteins, U.S. Provisional Patent Application No 61/681,654, filed August 10, 2012, entitled Modified Polynucleotides for the Production of Plasma Membrane Proteins, U.S. Provisional Patent Application No 61/737,152, filed December 14, 2012, entitled Modified Polynucleotides for the Production of Plasma Membrane Proteins, U.S. Provisional Patent Application No 61/618,885, filed April 2, 2012, entitled Modified Polynucleotides for the Production of Cytoplasmic and Cytoskeletal Proteins, U.S.
Load more

Recommended publications
  • PRIMARY HYPERHIDROSIS Prevalence and Impacts for the Individual
    PRIMARY HYPERHIDROSIS Prevalence and impacts for the individual Alexander Shayesteh Afshar Department of Public Health and Clinical Medicine Dermatology and Venereology Umeå 2018 Copyright © Alexander Shayesteh Afshar 2018 This work is protected by the Swedish Copyright Legislation (Act 1960:729) Dissertation for PhD ISBN: 978-91-7601-822-4 ISSN: 0346-6612 New Series No 1940 Cover art: “Drop Beads” by Grant Ware and Alexander Shayesteh Afshar Electronic version available at: http://umu.diva-portal.org/ Printed by: Umu Print Service Umeå, Sweden 2018 To Ladan, Gabriel and Isabell In medicine we ought to know the causes of sickness and health. And because health and sickness and their causes are sometimes manifest, and sometimes hidden and not to be comprehended except by the study of symptoms, we must also study the symptoms of health and disease. Avicenna 973-1037 CE Table of contents Abstract ............................................................................................ iii Abbreviations .................................................................................... v Sammanfattning på svenska ............................................................ vi List of papers .................................................................................. vii Introduction ....................................................................................... 1 Sweat ................................................................................................................................. 1 Sweat glands ....................................................................................................................
    [Show full text]
  • J.M. Azaña Defez, M.L. Martínez Martínez Doctors in Medicine and Surgery
    Acne J.M. Azaña Defez, M.L. Martínez Martínez Doctors in Medicine and Surgery. Consultant Physicians at the Dermatology Service. Pediatric Dermatology Unit. University Hospital Complex of Albacete Abstract Resumen Acne is a chronic inflammatory skin disease of El acné es una enfermedad cutánea inflamatoria the pilosebaceous unit of multifactorial etiology crónica del folículo pilosebáceo, de origen characterized by increased sebaceous secretion, multifactorial, caracterizada por: aumento de la comedone formation, inflammatory lesions and secreción sebácea, formación de comedones, lesiones risk of scarring sequelae. It is undoubtedly one inflamatorias y riesgo de secuelas cicatrizales. of the most frequent dermatological processes Es, sin duda, uno de los procesos dermatológicos in the daily clinical practice, especially in más frecuentes en la práctica clínica diaria, adolescence, although it can also appear in especialmente en la adolescencia, aunque también childhood and persist into adulthood. Adequate puede aparecer en niños y persistir en la edad management of this pathology is relevant, adulta. Es importante un manejo adecuado de esta as it can cause lower self-esteem and social patología, que puede producir una disminución de la dysfunction in patients, with the subsequent autoestima y disfunción social de los pacientes, con impact on quality of life. el consiguiente impacto en la calidad de vida. Key words: Cutibacterium acnes; Grading and classification of acne; Acne management; Isotretinoin. Palabras clave: Acné; Cutibacterium acnes; Graduación y clasificación del acné; Manejo del acné; Isotretinoina. Introduction Etiopathogenesis acne among the Spanish population Acne is a frequent inflammatory skin aged 12 to 18 years is 74%, without Acne is a multifactorial disease, produced disease of chronic course and polymor- significant differences regarding sex by: increased sebaceous secretion, follicu- phous in its clinical expression.
    [Show full text]
  • Prospective Observational Study in a Tertiary
    CLINICAL STUDY OF PROFILE OF ADOLESCENT DERMATOSES AND THEIR EFFECT ON QUALITY OF LIFE IN ADOLESCENTS – PROSPECTIVE OBSERVATIONAL STUDY IN A TERTIARY CARE HOSPITAL IN SOUTH INDIA Dissertation Submitted to THE TAMILNADU DR.M.G.R. MEDICAL UNIVERSITY IN PARTIAL FULFILMENT FOR THE AWARD OF THE DEGREE OF DOCTOR OF MEDICINE IN DERMATOLOGY, VENEREOLOGY & LEPROSY Register No.: 201730251 BRANCH XX MAY 2020 DEPARTMENT OF DERMATOLOGY VENEREOLOGY & LEPROSY TIRUNELVELI MEDICAL COLLEGE TIRUNELVELI -11 BONAFIDE CERTIFICATE This is to certify that this dissertation entitled “CLINICAL STUDY OF PROFILE OF ADOLESCENT DERMATOSES AND THEIR EFFECT ON QUALITY OF LIFE IN ADOLESCENTS – PROSPECTIVE OBSERVATIONAL STUDY IN A TERTIARY CARE HOSPITAL IN SOUTH INDIA” is a bonafide research work done by Dr.ARAVIND BASKAR.M, Postgraduate student of Department of Dermatology, Venereology and Leprosy, Tirunelveli Medical College during the academic year 2017 – 2020 for the award of degree of M.D. Dermatology, Venereology and Leprosy – Branch XX. This work has not previously formed the basis for the award of any Degree or Diploma. Dr.P.Nirmaladevi.M.D., Professor & Head of the Department Department of DVL Tirunelveli Medical College, Tirunelveli - 627011 Dr.S.M.Kannan M.S.Mch., The DEAN Tirunelveli Medical College, Tirunelveli - 627011 CERTIFICATE This is to certify that the dissertation titled as “CLINICAL STUDY OF PROFILE OF ADOLESCENT DERMATOSES AND THEIR EFFECT ON QUALITY OF LIFE IN ADOLESCENTS – PROSPECTIVE OBSERVATIONAL STUDY IN A TERTIARY CARE HOSPITAL IN SOUTH INDIA” submitted by Dr.ARAVIND BASKAR.M is a original work done by him in the Department of Dermatology,Venereology & Leprosy,Tirunelveli Medical College,Tirunelveli for the award of the Degree of DOCTOR OF MEDICINE in DERMATOLOGY, VENEREOLOGY AND LEPROSY during the academic period 2017 – 2020.
    [Show full text]
  • Impact of Photostability and UVA/UVA-Blue Light Protection On
    Thannhausen, Germany, August 06, 2019 Thannhausen, Germany, | Volume 145 Volume | 7+8/19 powered by skin whitening Natural Extremolyte Fights Pigmentation Caused by Environmental Stressors 7/8 Impact of Photostability 2019 english solubilizers Effective Natural Alternatives to Synthetic Solubilizers – a Comparison Study sun care and UVA/UVA-Blue Light Impact of Photostability and UVA/UVA-Blue Light Protection on Free Radical Generation Blue Light Induced Hyperpigmentation in Skin and How to Prevent it Photostabilisation: The Key to Robust, Protection on Free Radical Safe and Elegant Sunscreens disinfection Skin and Environmentally Safe and Universally Useable Disinfectant for all Generation Surfaces with Green Technology skin/hair care Natural Oil Metathesis Unveils High-Performance Weightless Cosmetic Emollients M. Sohn, S. Krus, K. Jung, M. Seifert, M. Schnyder SOFW Journal 7+8/19 | Volume 145 | Thannhausen, Germany, August 06, 2019 personal care | sun care Impact of Photostability and UVA/UVA-Blue Light Protection on Free Radical Generation M. Sohn, S. Krus, K. Jung, M. Seifert, M. Schnyder abstract he impact of UV-filter combination on the number of free radicals generated in sunscreen formulations and the skin follow- Ting UV-VIS irradiation was assessed via electron spin resonance spectroscopy using a spin-probing approach. Four UV-filter combinations that differed in their photostability and range of UVA absorbance coverage were investigated. Fewer free radicals were generated in the sunscreen formulation when a photostable UVA filter system was used, compared to a stabilized UVA fil- ter system. Additionally, fewer free radicals were generated in the skin when a sunscreen with long UVA protection extending to the short visible range was used, compared to a sunscreen with minimal UVA protection.
    [Show full text]
  • Copyrighted Material
    Part 1 General Dermatology GENERAL DERMATOLOGY COPYRIGHTED MATERIAL Handbook of Dermatology: A Practical Manual, Second Edition. Margaret W. Mann and Daniel L. Popkin. © 2020 John Wiley & Sons Ltd. Published 2020 by John Wiley & Sons Ltd. 0004285348.INDD 1 7/31/2019 6:12:02 PM 0004285348.INDD 2 7/31/2019 6:12:02 PM COMMON WORK-UPS, SIGNS, AND MANAGEMENT Dermatologic Differential Algorithm Courtesy of Dr. Neel Patel 1. Is it a rash or growth? AND MANAGEMENT 2. If it is a rash, is it mainly epidermal, dermal, subcutaneous, or a combination? 3. If the rash is epidermal or a combination, try to define the SIGNS, COMMON WORK-UPS, characteristics of the rash. Is it mainly papulosquamous? Papulopustular? Blistering? After defining the characteristics, then think about causes of that type of rash: CITES MVA PITA: Congenital, Infections, Tumor, Endocrinologic, Solar related, Metabolic, Vascular, Allergic, Psychiatric, Latrogenic, Trauma, Autoimmune. When generating the differential, take the history and location of the rash into account. 4. If the rash is dermal or subcutaneous, then think of cells and substances that infiltrate and associated diseases (histiocytes, lymphocytes, mast cells, neutrophils, metastatic tumors, mucin, amyloid, immunoglobulin, etc.). 5. If the lesion is a growth, is it benign or malignant in appearance? Think of cells in the skin and their associated diseases (keratinocytes, fibroblasts, neurons, adipocytes, melanocytes, histiocytes, pericytes, endothelial cells, smooth muscle cells, follicular cells, sebocytes, eccrine
    [Show full text]
  • Hyperhidrosis Hyperhidrosis Is a Condition Characterised by Abnormally Increased Sweating, in Excess of That Required for Regulation of Body Temperature
    20 Dermatology Hyperhidrosis Hyperhidrosis is a condition characterised by abnormally increased sweating, in excess of that required for regulation of body temperature. Hyperhidrosis can either be generalised or localised to specifc parts of the body, such as hands, feet and axillae. Hyperhidrosis can be divided into primary or idiopathic, and a secondary type. Te primary type usually starts during adolescence or even earlier, while secondary hyperhidrosis can start at any point in life. Te latter form may be due to a disorder of the thyroid or pituitary gland, diabetes mellitus, tumours, gout, menopause, or certain medications. Tis article highlights the clinical features and the treatment options for this condition. Nabil Aly, Consultant Physician, University Hospital Aintree, Liverpool email [email protected] Epidemiology Hyperhidrosis is sweating in axillae; localised hyperhidrosis, excess of that required for and generalised hyperhidrosis.1,2 normal thermoregulation. It is a Localised hyperhidrosis, unlike People of all ages can be afected condition that usually begins in generalised hyperhidrosis, by hyperhidrosis. Primary either childhood or adolescence usually begins in childhood or hyperhidrosis affects men and can affect any site on the adolescence. Localised unilateral and women equally, and most body. However, the sites most or segmental hyperhidrosis is commonly occurs among people commonly afected are the palms, rare and of unknown origin. aged 25–64 years. Some may soles, and axillae. Excessive The condition usually presents have been affected since early sweating may be primary on the forearm or forehead in childhood, and about 30–50% (idiopathic) or secondary to otherwise healthy individuals, have another family member medication use, certain diseases, without evidence of the typical afflicted, implying a genetic metabolic disorders, or febrile triggering factors found in predisposition.5 Localised illnesses.
    [Show full text]
  • Canadian Clinical Practice Guideline on the Management of Acne (Full Guideline)
    Appendix 4 (as supplied by the authors): Canadian Clinical Practice Guideline on the Management of Acne (full guideline) Asai, Y 1, Baibergenova A 2, Dutil M 3, Humphrey S 4, Hull P 5, Lynde C 6, Poulin Y 7, Shear N 8, Tan J 9, Toole J 10, Zip C 11 1. Assistant Professor, Queens University, Kingston, Ontario 2. Private practice, Markham, Ontario 3. Assistant Professor, University of Toronto, Toronto, Ontario 4. Clinical Assistant Professor, University of British Columbia, Vancouver, British Columbia 5. Professor, Dalhousie University, Halifax, Nova Scotia 6. Associate Professor, University of Toronto, Toronto, Ontario 7. Associate Clinical Professor, Laval University, Laval, Quebec 8. Professor, University of Toronto, Toronto, Ontario 9. Adjunct Professor, University of Western Ontario, Windsor, Ontario 10. Professor, University of Manitoba, Winnipeg, Manitoba 11. Clinical Associate Professor, University of Calgary, Calgary, Alberta Appendix to: Asai Y, Baibergenova A, Dutil M, et al. Management of acne: Canadian clinical practice guideline. CMAJ 2015. DOI:10.1503/cmaj.140665. Copyright © 2016 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at [email protected]. Contents List of Tables and Figures ............................................................................................................. v I. Introduction ................................................................................................................................ 1 I.1 Is a Clinical Practice Guideline
    [Show full text]
  • Copyrighted Material
    1 Index Note: Page numbers in italics refer to figures, those in bold refer to tables and boxes. References are to pages within chapters, thus 58.10 is page 10 of Chapter 58. A definition 87.2 congenital ichthyoses 65.38–9 differential diagnosis 90.62 A fibres 85.1, 85.2 dermatomyositis association 88.21 discoid lupus erythematosus occupational 90.56–9 α-adrenoceptor agonists 106.8 differential diagnosis 87.5 treatment 89.41 chemical origin 130.10–12 abacavir disease course 87.5 hand eczema treatment 39.18 clinical features 90.58 drug eruptions 31.18 drug-induced 87.4 hidradenitis suppurativa management definition 90.56 HLA allele association 12.5 endocrine disorder skin signs 149.10, 92.10 differential diagnosis 90.57 hypersensitivity 119.6 149.11 keratitis–ichthyosis–deafness syndrome epidemiology 90.58 pharmacological hypersensitivity 31.10– epidemiology 87.3 treatment 65.32 investigations 90.58–9 11 familial 87.4 keratoacanthoma treatment 142.36 management 90.59 ABCA12 gene mutations 65.7 familial partial lipodystrophy neutral lipid storage disease with papular elastorrhexis differential ABCC6 gene mutations 72.27, 72.30 association 74.2 ichthyosis treatment 65.33 diagnosis 96.30 ABCC11 gene mutations 94.16 generalized 87.4 pityriasis rubra pilaris treatment 36.5, penile 111.19 abdominal wall, lymphoedema 105.20–1 genital 111.27 36.6 photodynamic therapy 22.7 ABHD5 gene mutations 65.32 HIV infection 31.12 psoriasis pomade 90.17 abrasions, sports injuries 123.16 investigations 87.5 generalized pustular 35.37 prepubertal 90.59–64 Abrikossoff
    [Show full text]
  • International Journal of Scientific Research
    ORIGINAL RESEARCH PAPER Volume-9 | Issue-1 | January-2020 | PRINT ISSN No. 2277 - 8179 | DOI : 10.36106/ijsr INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH TYPES AND VARIANTS OF ACNE Dermatology Shailee Patel ABSTRACT Acne occur when pores of skin are blocked with oil, dead skin, or bacteria. It can occur when excessive oil is produced by follicles, bacteria build up in pores, and dead skin cells accumulate in pores. All these problem contribute in development of pimple. Acne are majorly seen among teenagers but they can also occur in adults. There are varying from of acne, and their varying treatment. KEYWORDS 1.INTRODUCTION ulcerative colitis and Crohn's disease and syndromes, such as Acne is linked to the change in hormone level during puberty. Acne is a synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) and disorder that is seen worldwide. Acne is a disease of the teenagers but pyogenic arthritis, pyoderma gangrenosum, and acne (PAPA) can be seen even in newborn children and also adults. Age and gender syndromes. also play a very important role in onset of acne. Acne most commonly occur between the ages of 10-13 years. Girls have an earlier onset 3.4 Occupational Acne which easily contribute to the onset of puberty in girls than in boys. The Occupational acne is defined as development of acne-like lesions after disease severity in more in boys during the late adolescence. Acne exposure to occupational agents in persons not prone to develop acne mostly develops on areas of skin that have abundant oil glands, like the and who have not had acne before engaging in the said occupation.
    [Show full text]
  • Revista6vol88ingles Layout 1 1/2/14 11:39 AM Página 1039 Página AM 11:39 1/2/14 1 Revista6vol88ingles Layout Revista6vol88ingles Layout 1 1/2/14 11:39 AM Página 1040
    Revista6Vol88ingles_Layout 1 1/2/14 11:39 AM Página 1039 ICONOGRAPHY 1039 s Drug-induced acne and rose pearl: similarities* Acne medicamentosa e a pérola rosa: semelhanças Rubens Pontello Junior 1 Rogerio Nabor Kondo 2 DOI: http://dx.doi.org/10.1590/abd1806-4841.20132586 Abstract: Drug-induced acne is a common skin condition whose classic symptoms can be similar to a rose pearl, as in the case of a male patient presenting with this condition after excessive use of a cream containing corticos- teroids. Keywords: Acneiform eruptions; Drug eruptions; Skin diseases Resumo: A acne medicamentosa é uma dermatose comum, que pode apresentar no seu quadro clássico seme- lhanças à pérola rosa, como no caso apresentado de um paciente do sexo masculino cujo quadro surgiu após uso intempestivo de creme contendo corticoesteróide. Palavras-chave: Dermatopatias; Erupção por droga; Erupções acneiformes Drug-induced acne, or drug-induced acneiform Discontinuation of the drug leads to remission eruption, is an adverse effect of a series of systemic of symptoms. Antihistamines are recommended in drugs, such as corticosteroids, lithium, vitamin B12, case of pruritus, and oral antibiotics are recommend- thyroid hormones, halogen compounds (iodine, ed in case of secondary infection with pustules or 2,3 bromine, fluorine, and chlorine), antibiotics (tetracy- impetiginization. cline and streptomycin), antituberculosis drugs We can observe the usual aspect of a papular (INH), lithium carbonate, antiepileptic drugs (pheno- follicular eruption and, on closer look, a small papule barbital and hydantoin derivatives), cyclosporin A, carefully surmounted by a pustule, which might be a antimycotics, gold salts, isotretinoin, clofazimine, epi- possible evolution into a vesiculopustule, as cited in dermal growth factor receptor inhibitors (cetuximab, the literature, demonstrating the inexorable aspect of gefitinib, and erlotinib), and interferon-beta.1,2 Usually, drug-induced acne (Figure 1).
    [Show full text]
  • Epidemiology and Pathogenetic Mechanisms of Polymorphic Light Eruption Janssens, A.S
    Epidemiology and pathogenetic mechanisms of polymorphic light eruption Janssens, A.S. Citation Janssens, A. S. (2008, January 17). Epidemiology and pathogenetic mechanisms of polymorphic light eruption. Retrieved from https://hdl.handle.net/1887/12576 Version: Corrected Publisher’s Version Licence agreement concerning inclusion of doctoral thesis in the License: Institutional Repository of the University of Leiden Downloaded from: https://hdl.handle.net/1887/12576 Note: To cite this publication please use the final published version (if applicable). 1 Introduction Introduction The research described in this thesis was initiated in 2002, when our group became member of the so-called SUNALL consortium. This was a multidisciplinary group of scientists from six different European countries interested in the pathogenesis of polymorphic light eruption (PLE). The scientific collaboration was funded by the European Commission. The main goal of the joint projects was to shed more light on pathogenetic mechanisms of PLE, but also to provide epidemiologic data, clues on mechanisms of (photo-) therapies and tools to improve diagnosis. A prerequisite was that all parties agreed on a definition of the studied subject. The clinical members of the SUNALL consortium reached consensus that polymorphic light eruption (PLE) is primarily a recurrent pruritic eruption comprising papules and/or vesicles and/or plaques, which occur on sun exposed skin sites, and which heal without scarring. We agreed to include patients with a classical history of PLE who also had positive ANA antibodies. However, the presence of antibodies against SSA and SSB was accepted as an exclusion criterion. Eczematous sun-induced lesions were not regarded as PLE.
    [Show full text]
  • High Levels of Free Radicals in Suncare Products Induce Acne Aestivalis in Sensitive Subjects
    personal care | sun care High Levels of Free Radicals in Suncare Products Induce Acne Aestivalis in Sensitive Subjects K. Jung*, U. Heinrich**, H. Tronnier**, M. Schnyder***, B. Herzog***, T. Herrling* PROOF READ VERSION ONLY abstract he market segment of suncare products for protection of sensitive skin against photodermatosis is growing. Specifically, pro- Ttection against Acne aestivalis (“Mallorca-Acne”) is perceived as a strong claim for this product category. There is evidence that peroxide free radicals, deriving from certain formulation components, are involved in the induction of photo-toxic skin reactions. These UV-induced free radicals can be assessed by an ESR-based method called Radical Potential (RP), by exposing formulations to UV radiation. The aim of this study was to find a correlation between the amount of UV inducible peroxides of sunscreen products and the clinical symptoms of Acne aestivalis. Two sunscreen formulas (SPF 30) containing organic UV-filters only, with an identical protection in the UV B region and a comparable protection in the UV A spectral range, have been pro- duced. For both formulations the amount of UV-inducible free radicals was assessed by the RP (Radical Potential). In addition, both formulas were tested in a clinical study with subjects with a history of Acne aestivalis. Very different RP values (levels of UV-induced free radicals) and completely different skin reactivity have been obtained, where an excellent correlation between the in vitro-parameter (RP) and the clinical symptoms could be shown. To our knowledge these results for the first time provide direct evidence for a strong correlation between UV inducible free radicals of formulations and the potential to induce A.
    [Show full text]